Kensey files 510(k) for embolic protection:
This article was originally published in Clinica
Kensey Nash has moved closer to entering the US market for embolic protection devices, after submitting a 510(k) marketing application to the FDA for its TriActiv system. The product is designed to prevent debris, dislodged during stenting procedures, from embolising downstream and causing adverse coronary events. It incorporates an embolic protection balloon, and a combined active flush and extraction system to remove the debris from the vessel. The 510(k) application contains data from a trial comparing TriActiv against other approved embolic protection systems for the treatment of saphenous vein graft (SVG) disease. The current market for embolic protection systems is estimated to approximate $100m worldwide and is expected to grow substantially over the next several years as next generation products are developed and as indications are expanded, said the Exton, Pennsylvania firm. The TriActiv system is approved in Europe for the SVG indication.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.